6O. Turrini,C. M. Schmidt,J. Moreno,P. Parikh,J. M. Matos,M. G. House,N. J. Zyromski,A. Nakeeb,H. A. Pitt,K. D. Lillemoe.Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?[J]. Journal of Gastrointestinal Surgery . 2009 (10)
7Shuichi Fujioka,Takeyuki Misawa,Tomoyoshi Okamoto,Takeshi Gocho,Yasuro Futagawa,Yuichi Ishida,Katsuhiko Yanaga.Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma[J]. Journal of Hepato - Biliary - Pancreatic Surgery . 2007 (6)
8Fritz S,Hackert T,Hinz Uet al.Role of serum carbohydrate antigen19-9and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. British Journal of Surgery . 2011
9D Marrelli,S Caruso,C Pedrazzani,A Neri,E Fernandes,M Marini.CA19–9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. The American Journal of Surgery . 2009
10Kim HR,Lee CH,Kim YW,Han SK,Shim YS,Yim JJ.Increased CA 19-9 level in patients without malignant disease. Clinical Chemistry and Laboratory Medicine . 2009
6Kai H, Kitadai Y, Kodama M, et al. Involvement of proinflammatory cytokines L 1 beta and L-6 in progression of human gastric carcinoma [J]. Anticancer Res, 2005, 25 (2A) :709-713.
7Ito R,Kitadai Y,Kyo E,et al. Interleukin-1 acts as an autocrine growth stimulator for human gastric carcinoma cell[J]. Cancer Res, 1993,53:4102-4106.
8Niwa T, Nivazaki T, Sotom M, et al. Interleukin-8 and biocompatibility of dialysis membranes[J]. Am J Nephrol, 1995,15: 181-185.
9Schneider MR, Hoeflich A, Fischer JR, et al. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells[J]. Cancer Lett, 2000, 151 (1) :31-38.
10Karczewska A, Nawrocki S, Breborowicz D, et al. Expression of ingerleukin-6, ingerleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma [J]. Cancer, 2000, 88 ( 9 ): 2061- 2071.
3Socnik K, Sosnik H. Some aspects of gallbladder carcinogenesis . Wiad Lek,2005,58(6) :678-681.
4Goonetilleke KS, Siriwardena AK. Systematic review of carbohy- drate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer[J]. Eur J Surg Oncol, 2007,33(2) : 266-270.
5Kannagi R. Carbohydrate antigen sialyl lewis aits pathophysiolog- ical sign{icance and induction meehansim in cancer progression [J]. Chang Gung Med J,2007,30(1) :189-209.
6Areteabala X, Riedeman JP,Roa I, et al. CA19-9 and carcinoem bryonic antigen in gallbladder eancer[J]. Rev Med Chil, 124( 1 ).- 11 2O.
7Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update o{ rec- ommendations {or the use of tumor markers in gastrointestna cancer [J]:1 Clin Oncol,2006,24(20) 5313-5327.
8DuI{y MJ,Dalen AV,Haglund C,et al. Tumor markers in colorec tal cancer: European Group on Tumor Markers (EGTM)guide- lines {or clinical use[J]. Eur Cancer,2007,43(9) 1348-1360.
9Mehta J, Prahu R, Eshpuniyani P, et al. Evaluating the efficacy of tumor markers CA19 9 and CEA to predi.ct operahillity and sur- vival in pancreatic malignancy EJ . Trop Gastroentrol, 2010, 31 (3) :190. S.
10tefanovic D, Novakovic R, persis-Savic M, et al. The evaluation of tumor markers levels in determination of surgical procedure in patients with gallbadder earcinoma[J]. Med Pregl, 46 (Suppl 1 ), s58-59.
